| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; YU-YUN SHAO; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:09Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Yih-Leong Chang;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:00Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-05T06:28:31Z |
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis
|
Guo J.-C.;Chang C.-C.;Yang C.-Y.;Liao B.-C.;Jau-Yu Liau;Chang C.-H.;Yeh K.-H.; Guo J.-C.; Chang C.-C.; Yang C.-Y.; Liao B.-C.; JAU-YU LIAU; Chang C.-H.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-05T06:28:31Z |
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis
|
Guo J.-C.;Chang C.-C.;Yang C.-Y.;Liao B.-C.;Jau-Yu Liau;Chang C.-H.;Yeh K.-H.; Guo J.-C.; Chang C.-C.; Yang C.-Y.; Liao B.-C.; JAU-YU LIAU; Chang C.-H.; Yeh K.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yu C.-J.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; TZU-HSIU TSAI; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Su K.-Y.; Chang Y.-L.; Liu Y.-N.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yu C.-J.; Yang J.C.-H.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2019-03-04T08:45:45Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Yang, J.;Yu, C. J.;Chang, Y. C.;Ho, C. C.;Lee, Y. F.;Lin, S. Y.;Lin, C. C.;Bai, Y. Y.;Liao, B. C.;JIN-YUAN SHIH; Liao, B. C.; Bai, Y. Y.; Lin, C. C.; Lin, S. Y.; Lee, Y. F.; Ho, C. C.; JIN-YUAN SHIH; Chang, Y. C.; Yu, C. J.; Yang, J. |
| 臺大學術典藏 |
2019-03-04T08:45:45Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Yang, J.;Yu, C. J.;Chang, Y. C.;Ho, C. C.;Lee, Y. F.;Lin, S. Y.;Lin, C. C.;Bai, Y. Y.;Liao, B. C.;JIN-YUAN SHIH; Liao, B. C.; Bai, Y. Y.; Lin, C. C.; Lin, S. Y.; Lee, Y. F.; Ho, C. C.; JIN-YUAN SHIH; Chang, Y. C.; Yu, C. J.; Yang, J. |
| 臺大學術典藏 |
2018 |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C; Bai Y.-Y; Lee J.-H; Chia-Chi Lin; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; Chih-Hsin Yang J; Yang P.-C. |
| 臺大學術典藏 |
2018 |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Chia-Lin Hsu;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2017 |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
|
Chih-Hsin Yang;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2017 |
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis
|
CHIN-CHEN CHANG; Yang C.-Y.; Liao B.-C.; Liau J.-Y.; Chang C.-H.; Yeh K.-H.; Guo J.-C.; Guo J.-C.;Chin-Chen Chang;Yang C.-Y.;Liao B.-C.;Liau J.-Y.;Chang C.-H.;Yeh K.-H. |
| 臺大學術典藏 |
2016 |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Liao B.-C.;Bai Y.-Y.;Lin C.-C.;Lin S.-Y.;Lee Y.-F.;Chao-Chi Ho;Shih J.-Y.;Chang Y.-C.;Yu C.-J.;Yang J.; Liao B.-C.; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; CHAO-CHI HO; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2016 |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Liao B.-C.; Bai Y.-Y.; Lin C.-C.; Lin S.-Y.; YEE-FAN LEE; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang J. |
| 臺大學術典藏 |
2015 |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
Yang J.C.H.; Shih J.Y; Chia-Chi Lin; Liao B.C |
